AnaptysBio, Inc.

NasdaqGS:ANAB 주식 리포트

시가총액: US$1.8b

AnaptysBio 경영진

경영진 기준 점검 4/4

AnaptysBio CEO는 Dan Faga, Mar2022 에 임명되었습니다 의 임기는 4.17 년입니다. 총 연간 보상은 $6.13M, 11.5% 급여 및 88.5% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $30.00M 가치에 해당하는 회사 주식의 1.71% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 2.3 년과 3.9 년입니다.

핵심 정보

Dan Faga

최고경영자

US$6.1m

총 보수

CEO 급여 비율11.51%
CEO 재임 기간4.2yrs
CEO 지분 보유율1.7%
경영진 평균 재임 기간2.3yrs
이사회 평균 재임 기간3.9yrs

최근 경영진 업데이트

Recent updates

Seeking Alpha • Apr 21

AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics

Summary AnaptysBio has spun off its biopharma pipeline into First Tracks Biotherapeutics, shifting to a royalty-focused, virtual business model. I maintain a "Hold" rating on both ANAB and TRAX, given the need for further clinical data and clarity on pipeline advancement and partnerships. ANAB retains royalty streams from JEMPERLI [GlaxoSmithKline] and imsidolimab (Vanda Pharmaceuticals), with JEMPERLI sales growing and a PDUFA date for imsidolimab set for Dec 2026. TRAX's value hinges on upcoming ANB033 data in celiac disease [Q4 2026] and EoE [mid-2027], and potential strategic financing for rosnilimab in RA Q2 2026. Read the full article on Seeking Alpha
분석 기사 • Jul 16

AnaptysBio, Inc.'s (NASDAQ:ANAB) Share Price Not Quite Adding Up

With a median price-to-sales (or "P/S") ratio of close to 8.6x in the Biotechs industry in the United States, you could...
분석 기사 • Jun 11

Shareholders May Be More Conservative With AnaptysBio, Inc.'s (NASDAQ:ANAB) CEO Compensation For Now

Key Insights AnaptysBio to hold its Annual General Meeting on 17th of June Salary of US$685.4k is part of CEO Dan...
분석 기사 • May 08

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

It's been a mediocre week for AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders, with the stock dropping 11% to US$19.68 in...
분석 기사 • May 07

Is AnaptysBio (NASDAQ:ANAB) Using Debt Sensibly?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Apr 03

AnaptysBio, Inc.'s (NASDAQ:ANAB) Price Is Right But Growth Is Lacking After Shares Rocket 30%

Despite an already strong run, AnaptysBio, Inc. ( NASDAQ:ANAB ) shares have been powering on, with a gain of 30% in the...
Seeking Alpha • Mar 06

AnaptysBio: A Shadow Of Its Former Self

Summary ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns. The recent deal for Imsidolimab reflects low confidence in the drug's market potential, despite positive phase 3 results. Rosnilimab showed promising trial results but failed to differentiate significantly from existing treatments, raising doubts about its competitive edge. Financials show a cash runway of 6-7 quarters, but high expenses and limited revenue sources maintain the risk profile. Read the full article on Seeking Alpha
분석 기사 • Feb 14

AnaptysBio, Inc. (NASDAQ:ANAB) Stock Rockets 29% As Investors Are Less Pessimistic Than Expected

AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders would be excited to see that the share price has had a great month...
Seeking Alpha • Dec 18

AnaptysBio: Doubts About Cash And Upcoming Rheumatoid Arthritis Readout

Summary The failure of ANB032 in Phase 2B for atopic dermatitis has shifted focus to rosnilimab, which faces significant competition and uncertain prospects. Rosnilimab's upcoming Phase 2B results for rheumatoid arthritis in February 2025 are crucial, but Eli Lilly's discontinuation of a similar drug raises concerns. If rosnilimab fails to deliver, the company's mid-stage pipeline may not hold much promise any more. Anaptys estimates that it will have about $415 million in the bank at the end of the year. Read the full article on Seeking Alpha
Seeking Alpha • Nov 21

AnaptysBio: An Immunology Pipeline-In-A-Pill Company Worth Watching

Summary AnaptysBio has been able to use its technology to develop 2 compelling lead drug candidates. Their pipeline has 2 key readouts in December 2024 and February 2025 worth monitoring. The near-term catalysts include a Phase 2b trial for the drug candidates rosnilimab and ANB032, which are crucial for re-evaluating AnaptysBio’s stock value. Despite this promising pipeline and experienced leadership team, the competitive landscape within immunology and potential clinical trial failures present substantial risks to AnaptysBio’s progress. Read the full article on Seeking Alpha
분석 기사 • Nov 07

AnaptysBio, Inc. (NASDAQ:ANAB) May Have Run Too Fast Too Soon With Recent 33% Price Plummet

The AnaptysBio, Inc. ( NASDAQ:ANAB ) share price has fared very poorly over the last month, falling by a substantial...
Seeking Alpha • Nov 01

AnaptysBio: Too Risky, Especially After GSK Drops Its Related Programs

Summary ANAB has a past history of successes. There are two molecules in phase 2, but with no patient data. The GSK news has hurt the stock. Read the full article on Seeking Alpha
Seeking Alpha • Aug 15

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Summary AnaptysBio, Inc. 14-week results from the phase 2b study, using ANB032 for the treatment of patients with moderate-to-severe Atopic Dermatitis, expected in December 2024. The global Atopic dermatitis market is expected to reach $19.49 billion by 2034. Top-line 12-week data from the phase 2b study, using rosnilimab for the treatment of patients with moderate-to-severe rheumatoid arthritis, expected in Q1 of 2025. The company raised $100 million in gross proceeds through a registered direct stock offering, substantially increasing its cash runway. Read the full article on Seeking Alpha
Seeking Alpha • Jul 08

AnaptysBio: Interesting Prospects, But Wait For The Dip (Rating Downgrade)

Summary AnaptysBio, Inc. receives a "Hold" rating for its U.S.-listed shares. It shows a 16.42% increase in stock market value since the last "Buy" rating. AnaptysBio's immunotherapy portfolio includes promising projects such as Rosnilimab, ANB032, ANB033, Imsidolimab, and Etokimab, with positive progress and the potential to develop into a profitable source of income. Financial partnership with GSK plc also bodes favorably with AnaptysBio's hopes for additional growth, despite a net loss in the first quarter of 2024. As in the past, the apparent continuation of Fed tightening for a longer period than market participants expect will create downward pressure. This analysis concludes that there are good reasons to believe that another sharp price drop is on the horizon. Read the full article on Seeking Alpha
분석 기사 • May 22

News Flash: Analysts Just Made A Captivating Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Forecasts

AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders will have a reason to smile today, with the analysts making substantial...
분석 기사 • May 12

Earnings Update: AnaptysBio, Inc. (NASDAQ:ANAB) Just Reported And Analysts Are Boosting Their Estimates

There's been a notable change in appetite for AnaptysBio, Inc. ( NASDAQ:ANAB ) shares in the week since its...
분석 기사 • Feb 22

Does AnaptysBio (NASDAQ:ANAB) Have A Healthy Balance Sheet?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
분석 기사 • Oct 10

Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

CEO 보수 분석

Dan Faga의 보수는 AnaptysBio의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Mar 31 2026n/an/a

-US$27m

Dec 31 2025US$6mUS$706k

-US$13m

Sep 30 2025n/an/a

-US$85m

Jun 30 2025n/an/a

-US$133m

Mar 31 2025n/an/a

-US$141m

Dec 31 2024US$14mUS$685k

-US$145m

Sep 30 2024n/an/a

-US$166m

Jun 30 2024n/an/a

-US$170m

Mar 31 2024n/an/a

-US$163m

Dec 31 2023US$7mUS$641k

-US$164m

Sep 30 2023n/an/a

-US$148m

Jun 30 2023n/an/a

-US$144m

Mar 31 2023n/an/a

-US$137m

Dec 31 2022US$25mUS$474k

-US$129m

Sep 30 2022n/an/a

-US$135m

Jun 30 2022n/an/a

-US$108m

Mar 31 2022n/an/a

-US$76m

Dec 31 2021US$310kn/a

-US$58m

보상 대 시장: Dan의 총 보수(USD6.13M)는 US 시장에서 비슷한 규모 기업의 평균(USD5.45M) 수준입니다.

보상과 수익: Dan의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Dan Faga (45 yo)

4.2yrs
재임 기간
US$6,133,943
보수

Mr. Daniel R. Faga, also known as Dan, is President, chief executive officer and Director of AnaptysBio, Inc. from August 2023. He was Interim President & CEO and Director of AnaptysBio, Inc. from March 21...

리더십 팀

이름직위재임 기간보수지분
Daniel Faga
President4.2yrsUS$6.13m1.71%
$ 30.0m
Christopher Murphy
Chief Financial Officerno data데이터 없음데이터 없음
Beth Mueller
Senior Vice President of Human Resources6.6yrs데이터 없음데이터 없음
Martin Dahl
Senior Vice President of Research4.3yrs데이터 없음데이터 없음
Benjamin Stone
Chief Business Officer2.3yrs데이터 없음데이터 없음
Monique Da Silva
Senior Vice President of Corporate Affairs2.3yrs데이터 없음데이터 없음
Priya Raina
Senior Vice President of Clinical Operations2.3yrs데이터 없음데이터 없음
Cailin Sibley
Senior Vice President of Translational Medicineno data데이터 없음데이터 없음
John Kwon
Vice President of GI Clinical Developmentno data데이터 없음데이터 없음
2.3yrs
평균 재임 기간
41yo
평균 나이

경험이 풍부한 관리: ANAB의 경영진은 경험이 있음으로 간주됩니다(평균 재임 2.3 년).

이사회 구성원

이름직위재임 기간보수지분
Daniel Faga
President4.5yrsUS$6.13m1.71%
$ 30.0m
John Orwin
Independent Chairman of the Board2.7yrsUS$370.23k0.037%
$ 644.3k
Hollings Renton
Lead Independent Director10.9yrsUS$426.69k0.017%
$ 299.9k
John Schmid
Independent Director10.9yrsUS$336.98k0.11%
$ 1.9m
Owen Hughes
Directorno data데이터 없음데이터 없음
Susannah Gray
Independent Directorless than a year데이터 없음데이터 없음
Oleg Nodelman
Independent Director5.1yrs데이터 없음데이터 없음
Dolca Thomas
Member of Scientific Advisory Board3.3yrs데이터 없음데이터 없음
Luisa Salter-Cid
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Christopher Hunter
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
John Monroe
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
3.9yrs
평균 재임 기간
60yo
평균 나이

경험이 풍부한 이사회: ANAB의 이사회는 경험이 있음으로 간주됩니다(평균 재임 3.9 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/22 13:57
종가2026/05/22 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

AnaptysBio, Inc.는 19명의 분석가가 다루고 있습니다. 이 중 6명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Neena Bitritto-GargBaird
Etzer DaroutBarclays
Michael KingCitizens JMP Securities, LLC